News
17/4/2020

IMIM becomes part of the European Consortium EATRIS to promote translational medicine

IMIM becomes part of the European Consortium EATRIS to promote translational medicine


News from IMIM


The IMIM Clinical Metabolomics Platform led by Oscar J. Pozo, from the IMIM Integrated Pharmacology and Systems Neuroscience Research Group, has become part of the EATRIS consortium, the European infrastructure for translational medicine, as part of the biomarker platform. This means that the Hospital del Mar Medical Research Institute (IMIM) is now part of a consortium comprising more than 80 prestigious European institutes that is aiming to establish synergies between healthcare researchers by providing them with the most advanced technologies and the experience needed to make headway in translational medicine.

EATRIS is a European Research Infrastructure Consortium (ERIC) whose main objective is to advance translational medicine. Translational research is a highly multidisciplinary and complex undertaking.  One of the greatest challenges in innovation is to understand which steps are necessary and the most appropriate technology and knowledge for taking these steps. EATRIS facilitates collaboration between healthcare professionals, basic researchers and companies. This makes EATRIS a unique forum for exchanging the know-how, requirements and techniques that promote and support the principles of translational research.

 

More information:
IMIM website